Data from: Micropulse transscleral cyclophotocoagulation results in secondary glaucoma
Data files
May 10, 2024 version files 14.77 KB
-
Data_Dryad.xlsx
12.22 KB
-
README.md
2.55 KB
Abstract
The aim of this study was to analyze the long-term outcome of first session of micropulse transscleral cyclophotocoagulation (MP-CPC) for refractory glaucoma developed after vitreoretinal surgery combined with silicone oil implantation. The inclusion criteria of this consecutive case series were: patients with secondary glaucoma in the refractory stage who underwent MP-CPC between 2018 and 2021, vitreoretinal surgery combined with silicon oil implantation, and at least a 24-month follow-up period after MP-CPC. Success was defined as the baseline eye pressure reduced at least 20%, and it should be ranged between 10 to 20 mmHg without further MP-CPC at the end of the follow-up. For this retrospective study, 11 eyes of 11 patients were selected. The reduction in IOP was found to be significant (p = 0.004) at the end of the follow-up time, and the success rate was 72% according to our results. The change in the number of antiglaucoma agents in the administered eyedrops was not significant compared to the baseline values. At the end of the follow-up period the change in BCVA values was not significant (p = 0.655). Our results confirm significant IOP lowering effect of this subthreshold method preserving visual performance safely even in eyes with previous vitrectomy surgery with a silicone oil implantation.
DOI: https://doi.org/10.5061/dryad.v6wwpzh1b
Description of the Data and file structure
We show 11 patients data. The vertical column shows the number of patients (1 to 11) and the horizontal row shows the variables tested in the different visits. The variables are shown in detail below:
- Age (years)
- Follow-up time (months)
- Number of MP-CPC sessions (MP-CPC: micropulse cyclophotocoagulation)
- Time of 2nd MP-CPC (in months compare4d to the first visit)
- BCVA first (logMAR) (BCVA: best corrected visual acuity; first: at baseline)
- BCVA last (logMAR) (BCVA: best corrected visual acuity; last: at the end of follow-up)
- Ta last (mmHg) (Ta: intraocular pressure, measured with Goldmann applanation tonometry; last: at the end of follow-up)
- 21+20% last (baseline eye pressure should be reduced at least 20% and it should be ranged between 10 to 20 mmHg; last: at the end of follow-up)
- comb first: (comb: combination = number of agents in the eyedrops; first: at baseline) (The name "overall" is used here to distinguish it from a later column with the same name, but the values are the same. It is included twice because at the beginning of the table we compared the data from the first and last visit.)
- comb last: (comb: combination = number of agents in the eyedrops; lasr: at the end of follow-up)
- ACTA first: (ACTA: orally applied acetazolamid; first: at baseline). (The name "overall" is used here to distinguish it from a later column with the same name, but the values are the same. It is included twice because at the beginning of the table we compared the data from the first and last visit.)
- ACTA last: (ACTA: orally applied acetazolamid; last: at the end of follow-up)
After these columns there are 4 variables to each visit (first, 3 months, 6 months, 9 months, 12 months, 15 months, 24 months, 36 months and 48 months):
- Ta (mmHg) (Ta: intraocular pressure) at each visit
- 21≤Ta first (intraocular pressure should be ranged between 10 to 20 mmHg; first: at baseline). After the first visit "21+20%" is used because intraocular pressure is comparable to the first (baseline) value.
- ACTA (ACTA: orally applied acetazolamid) at each visit
- comb (comb: combination = number of agents in the eyedrops) at each visit
Sharing/access Information
There is no other publicly accessible locations of the data:
Data was not derived from another source.
The patients in the study were examined at each visit and the data obtained during the examinations were recorded. Data were collected for a minimum of 24 months for all patients and up to 48 months for some patients. Statistical analysis was performed using IBM SPSS Statistics 25 (SPSS Inc., Chicago, IL, USA)